In summary, this candidate gene study revealed that candidate functional polymorphisms at RLN3, RXFP3, RXFP4, RLN2, and RXFP1 had no significant effects on the outcomes of MDD, atypical depression, anxiety, and metabolic syndrome. This evidence concerns the gene RXFP4 and Anxiety.